POZEN Inc

POZEN — BIO CEO & Investor Conference 2013

30 slides from POZEN's conference presentation, Feb 12, 2013

  1. Slide 1: BIO CEO & Investor Conference

    Slide 1: BIO CEO & Investor Conference

    Exhibit 99.1 BIO CEO & Investor Conference February 2013

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements The following presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forw

  3. Slide 3: POZEN's PA Franchise: Improving the Risk/Benefit Balance of Aspirin

    Slide 3: POZEN's PA Franchise: Improving the Risk/Benefit Balance of Aspirin

    POZEN ’s PAFranchise: Improving the Risk/Benefit Balance of Aspirin PA32540, PA8140, PA10040 and other PA product candidates are investigational new drugs. No claims, either expressed or implied, are made with respect to the safety or efficacy of the PA product candidates for the indications under i

  4. Slide 4: Key Message Take-Aways for Today

    Slide 4: Key Message Take-Aways for Today

    Key Message Take-Aways for Today Targeting NDA for PA32540 and PA8140 by April 2013 Positive top-line PA32540 Phase 3 results Seeking US and ROW commercial partner(s) to commercialize PA32540 / PA8140 / PA10040 • Ideal partner brings strong commercial capabilities and financial resources, as well as

  5. Slide 5: Longer Term Strategy Focused on Building Shareholder Value

    Slide 5: Longer Term Strategy Focused on Building Shareholder Value

    Longer Term Strategy Focused on Building Shareholder Value POZEN intends to maximize bottom line contribution from the PA franchise Limit ancillary expenditures Evaluation of current pipeline opportunities ongoing Only move additional programs into Phase 3 when partnered Management will remain focus

  6. Slide 6: PA32540: Positive Top-Line Results from Two Pivotal Phase 3 Studies

    Slide 6: PA32540: Positive Top-Line Results from Two Pivotal Phase 3 Studies

    PA32540: PositiveTop-LineResultsfrom Two Pivotal Phase 3 Studies Two Phase 3 pivotal trials under SPA • Total of 1,049 patients • Treatment with either PA32540 or EC ASA 325 mg once daily Primary endpoint met • Cumulative observed incidence of gastric ulcers over six months Key secondary endpoints m

  7. Slide 7: Significant Reduction of Gastric Ulcers, Gastro-duodenal Ulcers and Discontinuations with PA32540 at 6 Months

    Slide 7: Significant Reduction of Gastric Ulcers, Gastro-duodenal Ulcers and Discontinuations with PA32540 at 6 Months

    Significant Reduction of Gastric Ulcers, Gastro-duodenal Ulcers and Discontinuations with PA32540 at 6 Months 16 PA32540 EC ASA 325mg P < 0.001 14 71% P < 0.001 12 11.6 63% P < 0.001 10 82% 8.6 8.2 8 6 4 3.2 3.4 2 1.5 0 Gastric Ulcers Gastro-duodenal UlcersDiscontinuations: (Primary Endpoint) UGI AE

  8. Slide 8: Bioavailability

    Slide 8: Bioavailability

    Bioavailability Study PA32540-115 • The FDA has indicated that Study 115, together with additional information that will be submitted in the NDA, should constitute sufficient data to support the establishment of a bridge to Ecotrin ® (325 mg) Study PA8140-102 • Demonstratedthat PA8140hadcomparablebi

  9. Slide 9: PA Commercial Opportunity

    Slide 9: PA Commercial Opportunity

    >> BOLDOUTLOOK PA Commercial Opportunity WIPOZEN

  10. Slide 10: PACV: Addresses a High Unmet Medical Need

    Slide 10: PACV: Addresses a High Unmet Medical Need

    PACV:Addressesa HighUnmetMedicalNeed Large Patient base (U.S. alone) 1 • 24MM secondary prevention patients 2 • 60 -80%+ use daily aspirin already ACC & ACG 2008 * Clinical Consensus recommend PPIs for ASA-induced GI injury: 3 • 20% on low-dose aspirin are at risk for UGI AEs, e.g., gastric or duode

  11. Slide 11: Payer Market Research Findings: PA32540 Strong Payer Acceptance at $1.00/day

    Slide 11: Payer Market Research Findings: PA32540 Strong Payer Acceptance at $1.00/day

    PayerMarket ResearchFindings:PA32540 Strong PayerAcceptance at $1.00/day Payers’initial reservations not unexpected • “Both products are OTC or generic” • Many requested efficacy data vs. the separate components Affordable pricingchanged Payer view to positive • Pricingis the key component to intere

  12. Slide 12: Physician Market Research Findings: PA32540 Strong Physician Interest

    Slide 12: Physician Market Research Findings: PA32540 Strong Physician Interest

    PhysicianMarket Research Findings: PA32540 Strong Physician Interest to RX at $1.00/day Positive reaction to affordability (~$1/day) Would prescribe PA32540 or PA8140 for about 30% - 40% of secondary prevention patients 80+% of physicians would prescribe PA instead of separate components Compliance

  13. Slide 13: Patient Market Research Findings: PA32540 Significant Patient Interest

    Slide 13: Patient Market Research Findings: PA32540 Significant Patient Interest

    PatientMarket Research Findings: PA32540 Significant Patient Interest at ~$1.00/Day Patient Willingness to Pay ($ / Month) 52% ‘extremely’or ‘very’interested 100% 60% would ask their doctor about it 36% Willing to Pay at $30/month 75% 36% willing to pay • 46% on ASA+PPI $30/month 50% Cost/Month Toda

  14. Slide 14: PA's Potential Commercial Advantages

    Slide 14: PA's Potential Commercial Advantages

    PA’sPotential Commercial Advantages Affordable pricing(~$1.00/day) for a potentially life saving medication • Pricing at or near the sum of generic components remains profitable • Value of the product to be supported by a pharmaco-economic model Large target patient population Targeted physician aud

  15. Slide 15: Modeling the US Market Opportunity for PA32540/PA8140

    Slide 15: Modeling the US Market Opportunity for PA32540/PA8140

    Modeling the US Market Opportunity for PA32540/PA8140 $1,800 • There are 24MM CV secondary $1,500 1 prevention patients in the US 2 $1,200 • 95%+ of them take aspirin • Doctors would prescribe $900 PA32540/PA8140 for 30-40% of 2 $600 secondary prevention patients • 36% of patients would be willing t

  16. Slide 16: PA32540/PA8140: >$400 MM US Market Opportunity

    Slide 16: PA32540/PA8140: >$400 MM US Market Opportunity

    PA32540/ PA8140: >$400 MM US Market Opportunity Coordinated delivery of aspirin and omeprazole Affordable and convenient vs. taking two separate Differentiation products Global expansion opportunity Additional patent applications filed could extend to protection to 2022 -2030 Targeted Secondary prev

  17. Slide 17: PA Products are Protected by a Robust Patent Position

    Slide 17: PA Products are Protected by a Robust Patent Position

    PAProducts are Protected by a Robust Patent Position ‘A pharmaceutical composition in unit dosage form comprising an enteric-coated NSAID and a non-enteric- coated acid inhibitor formulated for coordinated release’ Two US Patents issued (expire 2/28/2023) • 6,926,907 issued 8/9/2005: Rights ex-aspir

  18. Slide 18: Aspirin Use in Cancer

    Slide 18: Aspirin Use in Cancer

    18 Aspirin Use in Cancer >> BOLDOUTLOOK IMPOZEN

  19. Slide 19: Consider the Benefit/Risk Profile of ASA in Cancer

    Slide 19: Consider the Benefit/Risk Profile of ASA in Cancer

    Consider the Benefit/Risk Profile of ASA in Cancer Benefits Risks • Strong anti-tumor effect • Risk profile primarily related demonstrated in various to antiplatelet activity and GI animal models toxicity • Compelling evidence for a • Perhaps the most well life prolonging effect of ASA known safety

  20. Slide 20: Cancer and ASA: What Is Being Studied

    Slide 20: Cancer and ASA: What Is Being Studied

    Cancer and ASA: What Is Being Studied 20

  21. Slide 21: Cancer and ASA: What Is Being Said

    Slide 21: Cancer and ASA: What Is Being Said

    Cancer and ASA: What Is Being Said Benefits: Based on solid evidence, daily aspirin for at least 5 years reduces CRC incidence and mortality. This is based on two reports of extended follow-up of two RCTs and meta-analysis of observational studies. A third report that adds extended follow-up of an a

  22. Slide 22: Cancer and ASA: What Is Being Said

    Slide 22: Cancer and ASA: What Is Being Said

    Cancer and ASA: What Is Being Said The American Cancer Society does not currently recommend taking aspirin as a colon cancer prevention measure, Jacobs emphasizes. "Aspirin, even at low doses, substantially increases the risk of serious, occasionally fatal, gastrointestinal bleeding," he says. "Curr

  23. Slide 23: Cancer and ASA: What Is Being Written

    Slide 23: Cancer and ASA: What Is Being Written

    Cancer and ASA: What Is Being Written 23

  24. Slide 24: Ongoing Clinical Studies with a Focus on Determining Aspirin's Effect on Cancer Outcomes

    Slide 24: Ongoing Clinical Studies with a Focus on Determining Aspirin's Effect on Cancer Outcomes

    Ongoing Clinical Studies with a Focus on Determining Aspirin’s Effect on Cancer Outcomes* Protocol Title Study Period Sponsor Estimated Enrollment Aspirin for Dukes C and High Risk Dukes 2007-2019 NationalCancerCentre,Singapore 2,660 B Colorectal Cancers Universityof Oxford The Effect Of Aspirin On

  25. Slide 25: Financial Overview

    Slide 25: Financial Overview

    25 Financial Overview >> BOLDOUTLOOK IMPOZEN

  26. Slide 26: VIMOVO Sales Growth in Q4 and 2012

    Slide 26: VIMOVO Sales Growth in Q4 and 2012

    VIMOVO Sales Growth in Q4 and 2012 Growth Growth $ (millions) Q4 vs. Q3 2012 vs. 2011 US VIMOVO Sales* $6m 79% $25m 19% ROW VIMOVO Sales* $12m 24% $40m 208% Global Sales* $18m 38% $65m 91% * As reported by AstraZeneca on 1/31/2013 26

  27. Slide 27: Key Financial Facts

    Slide 27: Key Financial Facts

    Key Financial Facts Financial Overview Net Cash at 6/30/12 $95.3 Million Net Cash at 9/30/12 $92.3 Million Shares Outstanding 30 Million Market Cap –2/8/13 $171 Million Self funding since IPO in 2000 2012 Results to be Reported 3/6/2013 27

  28. Slide 28: Key Message Take-Aways for Today

    Slide 28: Key Message Take-Aways for Today

    Key Message Take-Aways for Today Targeting NDA for PA32540 and PA8140 by April 2013 Positive top-line PA32540 Phase 3 results Seeking US and ROW commercial partner(s) to commercialize PA32540 / PA8140 / PA10040 • Ideal partner brings strong commercial capabilities and financial resources, as well as

  29. Slide 29: BIO CEO & Investor Conference

    Slide 29: BIO CEO & Investor Conference

    BIO CEO & Investor Conference February 2013

  30. Slide 30: PA32540: Substantial Market Research Conducted with Key Stakeholders

    Slide 30: PA32540: Substantial Market Research Conducted with Key Stakeholders

    PA32540: SubstantialMarket Research Conducted with Key Stakeholders* Payers Health Care Providers Patients (N=148) (N=4,000+) (N=2,600+) • Managed Care • Qual. Product Profile Testing & Forecast • Patient Incidence • Qual. Positioning, Attribute Testing & Forecast Advisory Panel Study Update • Payer

Source: SEC EDGAR · 8-K filed Feb 12, 2013

More decks from POZEN Inc